Mechanisms of Local Immunoresistance in Glioma

被引:58
作者
Albesiano, Emilia [2 ]
Han, James E. [1 ]
Lim, Michael [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21231 USA
[2] Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA
关键词
Glioblastoma multiforme; Immunotherapy; Oncogenic signaling pathway; Immunoresistance; ENDOTHELIAL GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; PRIMARY INTRACRANIAL TUMORS; FAS LIGAND EXPRESSION; REGULATORY T-CELLS; HUMAN GLIOBLASTOMA CELLS; CONFER IMMUNE PRIVILEGE; PERIPHERAL-BLOOD; IN-VIVO; INDOLEAMINE 2,3-DIOXYGENASE;
D O I
10.1016/j.nec.2009.08.008
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Even though the central nervous system (CNS) was conventionally defined as "immunologically privileged", new discoveries have demonstrated the role of the immune system in neurologic disease and illness, including gliomas. Brain tumor immunotherapy is an exciting and revived area of research, in which neurosurgeons have taken a major position. Despite the ability to induce a tumor-specific systemic immune response, the challenge to effectively eradicate intracranial gliomas remains mainly because of tumor-induced immunoresistance. This article gives an overview of the immunologic responses that occur in the CNS and their potential role in brain tumors. The main cellular and molecular mechanisms that mediate tumor escape from natural immune surveillance are also covered in this article. Glioma cells have been shown to diminish the expression of danger signals necessary for immune activation and to increase the concentration of immunosuppressive factors in the tumor microenvironment, which results in T-cell anergy or apoptosis. Finally, the authors discuss most of the over-expressed oncogenic signaling pathways that cause tumor tolerance.
引用
收藏
页码:17 / +
页数:14
相关论文
共 163 条
[31]   Cancer immunoediting: from immunosurveillance to tumor escape [J].
Dunn, GP ;
Bruce, AT ;
Ikeda, H ;
Old, LJ ;
Schreiber, RD .
NATURE IMMUNOLOGY, 2002, 3 (11) :991-998
[32]  
ELLIOTT LH, 1984, J IMMUNOL, V132, P1208
[33]   Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors [J].
Facoetti, A ;
Nano, R ;
Zelini, P ;
Morbini, P ;
Benericetti, E ;
Ceroni, M ;
Campoli, M ;
Ferrone, S .
CLINICAL CANCER RESEARCH, 2005, 11 (23) :8304-8311
[34]   Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. [J].
Fecci, PE ;
Mitchell, DA ;
Whitesides, JF ;
Xie, WH ;
Friedman, AH ;
Archer, GE ;
Herndon, JE ;
Bigner, DD ;
Dranoff, G ;
Sampson, JH .
CANCER RESEARCH, 2006, 66 (06) :3294-3302
[35]  
FONTANA A, 1984, J IMMUNOL, V132, P1837
[36]  
Fortin S., 2008, BRAIN PATHOL
[37]   T cell proliferation is blocked by indoleamine 2,3-dioxygenase [J].
Frumento, G ;
Rotondo, R ;
Tonetti, M ;
Ferrara, GB .
TRANSPLANTATION PROCEEDINGS, 2001, 33 (1-2) :428-430
[38]   Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells [J].
Gabrilovich, DI ;
Chen, HL ;
Cunningham, HT ;
Meny, GM ;
Nadaf, S ;
Kavanaugh, D ;
Carbone, DP .
NATURE MEDICINE, 1996, 2 (10) :1096-1103
[39]  
Gastman BR, 1999, CANCER RES, V59, P5356
[40]   IMPAIRED IMMUNOCOMPETENCE IN PATIENTS WITH MALIGNANT GLIOMAS - THE POSSIBLE ROLE OF LYMPHOCYTE-TG SUB-POPULATIONS [J].
GEROSA, MA ;
OLIVI, A ;
ROSENBLUM, ML ;
SEMENZATO, GP ;
PEZZUTTO, A .
NEUROSURGERY, 1982, 10 (05) :571-573